Theranostics Health to Launch HER Signaling Assay, Marking Firm's First Commercial Test Release | GenomeWeb

Theranostics Health this week announced the June launch of its first commercial test, a 14-protein assay for profiling activation of the HER signaling network.

The test, named the TheraLink HER Family Assay, is intended as a supplement to conventional HER2 testing for guiding therapy in breast cancer patients. The company plans an initial focus on metastatic cases where there are few existing treatment guidelines, Theranostics President and CEO Glenn Hoke told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.